Los Angeles Capital Management LLC Acquires 82,068 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

Los Angeles Capital Management LLC grew its stake in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 47.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 254,125 shares of the company's stock after purchasing an additional 82,068 shares during the quarter. Los Angeles Capital Management LLC owned approximately 0.83% of Medpace worth $77,897,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of MEDP. RiverPark Advisors LLC bought a new position in Medpace during the fourth quarter worth about $26,000. Contravisory Investment Management Inc. bought a new position in Medpace during the fourth quarter worth about $26,000. FinTrust Capital Advisors LLC bought a new position in Medpace during the third quarter worth about $30,000. GAMMA Investing LLC bought a new position in Medpace during the fourth quarter worth about $30,000. Finally, McGlone Suttner Wealth Management Inc. bought a new position in Medpace during the fourth quarter worth about $33,000. 77.98% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

MEDP has been the topic of a number of recent research reports. UBS Group raised shares of Medpace from a "neutral" rating to a "buy" rating and raised their price target for the stock from $282.00 to $452.00 in a research report on Thursday, February 15th. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Medpace in a report on Monday, March 18th. They issued a "hold" rating and a $395.00 target price on the stock. Guggenheim raised their target price on shares of Medpace from $453.00 to $464.00 and gave the company a "buy" rating in a report on Wednesday, April 24th. StockNews.com raised shares of Medpace from a "hold" rating to a "buy" rating in a report on Tuesday, April 23rd. Finally, Robert W. Baird raised their target price on shares of Medpace from $446.00 to $454.00 and gave the company an "outperform" rating in a report on Wednesday, April 24th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat, Medpace currently has an average rating of "Moderate Buy" and an average target price of $443.00.

Insider Buying and Selling

In related news, CEO August J. Troendle sold 15,102 shares of Medpace stock in a transaction that occurred on Monday, April 29th. The shares were sold at an average price of $400.69, for a total transaction of $6,051,220.38. Following the sale, the chief executive officer now directly owns 791,541 shares in the company, valued at approximately $317,162,563.29. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In other news, major shareholder Medpace Investors, Llc sold 13,988 shares of the business's stock in a transaction that occurred on Tuesday, February 20th. The shares were sold at an average price of $386.39, for a total value of $5,404,823.32. Following the transaction, the insider now owns 5,525,959 shares in the company, valued at approximately $2,135,175,298.01. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO August J. Troendle sold 15,102 shares of the business's stock in a transaction that occurred on Monday, April 29th. The stock was sold at an average price of $400.69, for a total transaction of $6,051,220.38. Following the completion of the transaction, the chief executive officer now owns 791,541 shares in the company, valued at approximately $317,162,563.29. The disclosure for this sale can be found here. Insiders have sold a total of 204,442 shares of company stock worth $82,702,867 in the last ninety days. Company insiders own 20.30% of the company's stock.

Medpace Stock Performance

Shares of MEDP traded down $6.79 during mid-day trading on Thursday, reaching $391.07. The company had a trading volume of 230,439 shares, compared to its average volume of 250,820. The company's 50 day simple moving average is $398.27 and its 200 day simple moving average is $329.37. Medpace Holdings, Inc. has a 1-year low of $197.39 and a 1-year high of $421.00. The company has a market capitalization of $12.12 billion, a price-to-earnings ratio of 39.86, a P/E/G ratio of 1.93 and a beta of 1.40.

Medpace (NASDAQ:MEDP - Get Free Report) last posted its earnings results on Monday, April 22nd. The company reported $3.20 EPS for the quarter, topping the consensus estimate of $2.45 by $0.75. Medpace had a net margin of 15.92% and a return on equity of 59.74%. The business had revenue of $511.00 million for the quarter, compared to the consensus estimate of $512.39 million. During the same period last year, the company earned $2.27 EPS. The firm's revenue was up 17.7% compared to the same quarter last year. As a group, equities analysts forecast that Medpace Holdings, Inc. will post 11.23 earnings per share for the current fiscal year.

Medpace Company Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.